A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC
Status:
Terminated
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether combining ganetespib (STA-9090) with
docetaxel is more effective than docetaxel alone in the treatment of patients with advanced
non-small cell lung cancer.